Argenica (ASX:AGN) show ARG-007 reducing traumatic brain injuries

Argenica Therapeutics’ novel treatment to reduce brain tissue death after stroke, ARG-007, has been shown on a preclinical rat model at Curtin University and the Perron Institute to significantly reduce damage to braincells caused by moderate traumatic brain injury.

The key proteins which contribute to brain injury and death after an injury like a punch to the ground or a car crash were found to be equivalent to uninured animals after being treated with ARG-007, and the brain inflammation which can cause damage far beyond the initial injury also returned to unharmed levels.

Treated animals were also much improved in functional outcomes, showing increased weight gain, reduced anxiety, and sustained improvement in balance, providing Argenica evidence its treatment protects against brain injuries.

Argenica Managing Director Liz Dallimore said the company was extremely pleased with the results from its first preclinical study on a moderate traumatic brain injury animal model.

 “The study indicates that injury caused by moderate traumatic brain injury may be limited by the introduction of ARG-007 shortly thereafter, so we are extremely encouraged by this data. We now look forward to undertaking further studies, supported by funds provided by our CRC-P grant, to provide greater evidence of ARG-007’s efficacy in TBI before establishing a clinical program of work,” Dr Dallimore said.

Developed as a treatment for ischaemic stroke patients, phase one trials successfully demonstrated that all doses of ARG-007 were safe and well-tolerated, propelling the Perth-based company to phase 2 planning which is already well advanced.

And with potential uses across a wide range of neurological issues, Argenica has secured over $4 million in grants and philanthropic funding to support work on potential applications including hypoxic ischaemic encephalopathy and Alzheimer’s Disease.

Public awareness about brain injuries and their potential long-term consequences has risen across recent years, and governments and health care systems are increasingly recognising the importance of brain injury treatment and rehabilitation.

AGN.AX

ARGENICA FPO [AGN]

ASX

$0.685

$0.005

0.74%

ARGENICA FPO [AGN]

Sector: Healthcare

Industry: Biotechnology

Employees:

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.